Axxam SpA
Axxam SpA
08/12/2026 | Press release | Archived content
Axxam validates cardiac organoid platform from Molecular Devices and HeartBeat.bio
- About Us
-
Discovery Solutions
- News & Resources
- Webinars & Events
- Careers
- Contact Us
- About Us
-
Discovery Solutions
- News & Resources
- Webinars & Events
- Careers
- Contact Us
Axxam Newsletter
Stay Ahead of Early Drug Discovery Breakthroughs!
Discover a world of opportunities in early drug discovery services through our newsletter.
Don't miss out on the latest webinars, events and news!
Subscribing to this newsletter, you consent to have your submitted information stored and used for contact purposes, as described in the Axxam privacy policy and cookie policy. The newsletter service is delivered in compliance with the privacy policy of the company; the service provides the possibility to "unsubscribe" or "update your preferences".
Δ
You will receive the most relevant information regarding our science and company.
Receive invites to webinars with hot scientific topics
Receive updates on new articles of our science blog
Find us on:
Newsletter
Do you want to know what we are doing?
Subscribe to the newsletter and stay updated on news
Axxam S.p.A.
Openzone - Via Meucci, 3
20091 Bresso - Milan, Italy
Cap. Soc.: euro 137.477 i.v.
C.F./P.IVA/VAT: IT13451210150
R.E.A. Milan 1653022
Follow us
Copyright © 2026 Axxam S.p.A.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Axxam SpA published this content on August 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 13, 2026 at 05:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]